Bio-Techne Corporation develops and sells life science reagents and instruments, valued at $8.4 billion. However, its stock has underperformed, declining 26% in 2025. Despite beating Q4 expectations, analysts predict a 2.9% EPS growth for fiscal 2026. Analysts rate the stock a “Moderate Buy,” with a price target of $61 and a potential upside of 14.5%.

Read more at Yahoo Finance: Bio-Techne Stock: Analyst Estimates & Ratings